Jianfei Luo

Dr. Jianfei Luo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
BQBing Qu
Bing Qu
JLJiasheng Liu
Jiasheng Liu
ZPZhiyang Peng
Zhiyang Peng
ZXZhe Xiao
Zhe Xiao
SLShijun Li
Shijun Li
JLJianfei Luo
Jianfei Luo
Cisplatin‐based chemotherapy is often used in advanced gastric cancer (GC) treatment, yet resistance to cisplatin may lead to treatment failure. Mechanisms underlying cisplatin resistance remain unclear. Recent evidence highlighted the role of macrophages in cancer chemoresistance. Macrophage‐derived exosomes were shown to facilitate intercellular communication. Here, we investigated the cisplatin resistance mechanism based on macrophage‐derived exosomes in gastric cancer. Cell growth and apoptosis detection experiments revealed that M2‐polarized macrophages increased the resistance of GC cells to cisplatin. qRT‐PCR, RNAase R assay, actinomycin D assay and cell nucleo‐cytoplasmic separation experiments confirmed the existence of circTEX2 in macrophage cytoplasm, with a higher expression level in M2 macrophages than that in M1 macrophages. Further experiments showed that circTEX2 acted as microRNA sponges for miR‐145 and regulated the expression of ATP Binding Cassette Subfamily C Member 1 (ABCC1). Inhibition of the circTEX2/miR‐145/ABCC1 axis blocked the cisplatin resistance of gastric cancer induced by M2 macrophages, as evidenced by in vitro and in vivo experiments. In conclusion, our research suggests that the exosomal transfer of M2 macrophage‐derived circTEX2 enhances cisplatin resistance in gastric cancer through miR‐145/ABCC1. Additionally, communication between macrophages and cancer cells via exosomes may be a promising therapeutic target for the treatment of cisplatin‐resistant gastric cancer.

23 August 2023 in Gene
Verified
Journal Article
Closed access
BQBing Qu
Bing Qu
JLJiasheng Liu
Jiasheng Liu
ZPZhiyang Peng
Zhiyang Peng
ZXZhe Xiao
Zhe Xiao
SLShijun Li
Shijun Li
JLJianfei Luo
Jianfei Luo

1 June 2026 in Frontiers in Aging
Verified
Journal Article
Open access
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
QTQiang Tong
Qiang Tong
BQBing Qu
Bing Qu
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
JLJianfei Luo
Jianfei Luo
Researchers now see aging as a process shaped by the interactions among metabolism, epigenetics, and hormones. Recent studies suggest that gut microbes play an important role in this system by making metabolites that can affect gene expression and chromatin structure. Still, it is not fully clear how gut microbes and the body influence each other as we age, since both are constantly changing. This review brings together current research on how metabolites from gut microbes—such as short-chain fatty acids, bile acids, tryptophan derivatives, and polyamines—affect the body’s epigenetic machinery through processes such as DNA methylation, histone modifications, and chromatin remodeling. We examine evidence from cell studies, animal experiments, and human research to assess the strength of the links and distinguish direct effects on chromatin from indirect metabolic or gene-expression changes. We focus especially on endocrine and reproductive organs, such as the hypothalamus, pancreas, liver, fat tissue, and cells that support the gonads, where signals from gut microbes overlap with hormonal control and metabolism. In these tissues, microbial metabolites influence key pathways related to inflammation, mitochondria, and nutrient sensing, but there is still little direct evidence in humans. The review also points out differences between lab models and what is observed in patients, highlighting the need for further work to apply these findings in real-world settings. Interactions between gut microbes and epigenetics form a two-way link between metabolism, immunity, and aging of the endocrine system. While more evidence shows that microbial metabolites can shape gene activity and epigenetic patterns, most of what we know comes from animal studies rather than direct tests in people. Moving forward, researchers will need to use broad, long-term studies that combine different types of data to figure out cause and effect and which tissues are involved. Understanding this system better could help create new biomarkers and treatments to influence aging by targeting the microbiome and its effects on epigenetics.

23 September 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KLKai Li
Kai Li
WSWei Song
Wei Song
YZYuefeng Zhang
Yuefeng Zhang
JLJianfei Luo
Jianfei Luo
Colorectal cancer (CRC) remains a major global health burden with high mortality rates, underscoring the need for effective therapies. This study explores the acetylation characteristics in CRC using single-cell RNA sequencing (scRNA-seq) and weighted gene co-expression network analysis (WGCNA), assessing their relationship with prognosis and the immune microenvironment. We analyzed two scRNA-seq datasets from the GEO database to identify distinct cell subtypes. Acetylation activity scores were calculated using the ssGSEA method. A WGCNA was constructed to identify gene modules associated with acetylation. An acetylation-related prognostic signature (ARPS) was developed, and its clinical significance was evaluated through survival analysis and immune landscape characterization. Acetylation activity was significantly elevated in epithelial, endothelial, and stromal cells. Based on the results of scRNA-seq, WGCNA identified 169 acetylation-related genes. Intersection with 1,691 acetylation-related differentially expressed genes (DEGs) yielded 131 common genes. Combining clinical data with the expression profiles of these genes, we employed 101 machine learning algorithms to develop an ARPS that accurately predicts the prognosis of CRC patients. Low-risk patients showed increased infiltration of immune cells, enhanced immune function, and better responses to immunotherapy. These findings underscore the clinical significance of acetylation features in CRC prognosis and immune response, highlighting their potential as biomarkers and therapeutic targets.

6 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
BQBing Qu
Bing Qu
YTYong-Qing Tong
Yong-Qing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
Background: Detection of colorectal cancer (CRC) currently relies mainly on invasive procedures such as colonoscopy. In experimental models, tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling. Building on these published insights, this study evaluated whether a panel of biomarkers previously associated with hypoxia-related processes, plasma methylated SEPT9 (mSEPT9), urinary N1, N12-diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, and LMR)—could be combined into a non-invasive diagnostic panel and compared with standard serum tumor markers. This study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. This study was conducted in a clinical diagnostic setting (patients with confirmed CRC, polyps, or benign surgical conditions) and does not represent a population-based screening cohort. Limitations include the lack of an external validation cohort; all analyses were performed on a single dataset, and the reported performance metrics may be optimistic. Independent validation is required before clinical implementation. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, and AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable logistic regression. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905). Conclusions: A multimarker panel of biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a non-invasive diagnostic approach for CRC detection in a clinical case–control setting. Validation in asymptomatic screening populations is required before any screening claim can be made. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes was not obtained and requires future investigation.

30 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
BQBing Qu
Bing Qu
YTYong-Qing Tong
Yong-Qing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
Background: Early detection of colorectal cancer (CRC) still relies mainly on invasive screening. Tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling in experimental models. Building on these insights, this study evaluated whether hypoxia pathway biomarkers—plasma methylated SEPT9 (mSEPT9), urinary N¹, N¹² diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, LMR)—could be combined into a noninvasive diagnostic panel compared with standard serum tumor markers. The study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable modeling. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905).” Conclusions: A multimarker panel of previously reported hypoxia-associated biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a scalable, noninvasive approach for CRC detection with high diagnostic accuracy. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes in patients was not obtained and requires future investigation.